Enlivex Therapeutics Ltd. has announced positive topline data from the Phase IIa stage of their clinical trial ENX-CL-05-001, which evaluates the efficacy of Allocetra™ in treating patients with moderate-to-severe knee osteoarthritis. The trial, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled study, demonstrated significant improvements in the treatment arm. In the modified intention-to-treat population, there was a 24% reduction in knee pain and a 26% improvement in knee function. Notably, in age-related primary osteoarthritis patients, a 72% reduction in knee pain and a 95% improvement in knee function were observed compared to placebo. The treatment also exhibited a favorable safety profile with no severe adverse events reported. The results were presented during a webinar held on August 18, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.